ORN Study: Curative Treatment of Osteoradionecrosis (ORN) With Hybrid Bone Substitution (ORN)
10 Patients Bicentric Prospective Study of Hybrid Bone Substitution With Calcium-phosphate Ceramic Biomaterial and Autologous Bone Marrow for Mandibular Osteoradionecrosis (ORN) Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nantes, France, 44093
- Nantes university hospital
-
Rennes, France, 35000
- Rennes University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients (between 18 and 75 years) affiliated with an appropriate social security system, diagnosed as suffering from symptomatic ORN, radiologically confirmed, for which surgery is indicated
- Presence maximum of 2 outbreaks of ORN
- Oncological remission of the original tumor site for 1 year and for 3 years if the ORN is in the contact or close to the initial tumoral site
- ECOG performance status 0, 1 or 2
- ORN symptomatic accessible to the conservation of at least one cortical mandibular basilar
- Signed informed consent
Exclusion Criteria:
- Oncological treatment
- Haematologic background
- Current bone necrosis consecutive or concurrent to taking bisphosphonates
- Extension of ORN does not allow the retention of a mandibular rod (bicortical form)
- Presence of fracture complicating ORN
- Bisphosphonates during the last year
- Contraindications to the removal of iliac or sternum bone marrow
- Contraindication for general anesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hybrid bone substitution
Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow
|
The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The cure of ORN
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
|---|---|
|
Quality of life
|
|
|
Evaluation of post operative pain at mandibular and bone marrow sampling site
|
|
|
Possibility of secondary dental prosthetic devices
|
|
|
CT semiology description of the treated area
|
|
|
Bone regeneration
|
Bone regeneration: kinetics of formation of new bone and biomaterial resorption
|
|
Number of hospital days
|
|
|
Safety of hybrid bone substitution
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Olivier Malard, Pr, Nantes university hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BRD/08/10-H
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.